{"product_id":"castlebiosciences-business-model-canvas","title":"Castle Biosciences Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBusiness Model Canvas for Precision Oncology Diagnostics - Investor-ready Strategic Blueprint\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the strategic blueprint behind Castle Biosciences with our Business Model Canvas. This concise analysis maps value propositions, customer segments, key partners and revenue engines. Perfect for investors and strategists seeking actionable insights. Download the full, editable Word\/Excel canvas to benchmark and apply these strategies today.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCollaborations with academic cancer centers, including NCI-designated centers (72 as of 2024), enable robust clinical validation studies and prospective registries. These partners provide access to diverse patient populations within the ~1.96 million new US cancer cases projected in 2024 and high-quality biospecimens. Joint publications bolster credibility with clinicians and payers, while co-development agreements accelerate assay refinement and new indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDermatology \u0026amp; oncology networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePartnerships with physician groups and KOLs accelerate guideline adoption and embed Castle Biosciences tests into oncology and dermatology workflows, with advisory input shaping test utility, cutoffs and reporting formats. Advisors and network feedback loops—supported by over 100 peer‑reviewed publications—drive continuous improvement. Pilot programs have documented measurable shifts in care decisions and uptake in real‑world settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer \u0026amp; PBM relationships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEngagement with Medicare, commercial insurers, and PBMs secures coverage policies and fair reimbursement for Castle Biosciences diagnostics in 2024, enabling broader patient access. Value dossiers and real-world outcomes data underpin negotiations and drive favorable formulary placement. Active medical policy advocacy ensures indications are recognized, while joint outcomes studies align incentives around cost-effective care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSequencing \u0026amp; reagent suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eVendors supply instruments, kits and QC materials that underpin Castle Biosciences assays, with supply agreements in 2024 helping lock pricing and continuity amid normalized post‑pandemic lead times; co-validation with suppliers reduces lot‑to‑lot variability and technical support accelerates troubleshooting and scale‑up.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupply agreements: pricing stability\u003c\/li\u003e\n\u003cli\u003eCo-validation: lower lot variability\u003c\/li\u003e\n\u003cli\u003eTechnical support: faster scale‑up\u003c\/li\u003e\n\u003cli\u003eInstruments\/kits\/QC: assay reliability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEHR\/LIS \u0026amp; integration partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInteroperability partners enable electronic ordering, results delivery, and point-of-care decision support, driving faster test turnaround and clinician adoption; as of 2024 over 95% of US hospitals use EHRs (ONC), increasing integration opportunity. HL7\/FHIR and LIS integrations reduce friction and errors by standardizing data flows and enabling automated result ingestion. Embedded clinical pathways boost utilization, while connected data streams support outcomes tracking and payer-evidence generation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInteroperability: electronic orders + results\u003c\/li\u003e\n\u003cli\u003eStandards: HL7\/FHIR + LIS reduce errors\u003c\/li\u003e\n\u003cli\u003eUtilization: embedded pathways increase use\u003c\/li\u003e\n\u003cli\u003eEvidence: data connectivity enables outcomes\/payer support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValidated at \u003cstrong\u003e72\u003c\/strong\u003e NCI centers; reaches \u003cstrong\u003e1.96M\u003c\/strong\u003e US cases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCastle partners with 72 NCI‑designated centers (2024) and physician KOLs to validate assays across ~1.96M projected US cancer cases in 2024, supported by 100+ peer‑reviewed publications. Payer engagement yielded Medicare\/commercial coverage in key indications, while HL7\/FHIR integrations and 95% hospital EHR adoption accelerate ordering and outcomes capture.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic centers\u003c\/td\u003e\n\u003ctd\u003e72 NCI\u003c\/td\u003e\n\u003ctd\u003eClinical validation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket size\u003c\/td\u003e\n\u003ctd\u003e1.96M new cases\u003c\/td\u003e\n\u003ctd\u003ePatient access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublications\u003c\/td\u003e\n\u003ctd\u003e100+\u003c\/td\u003e\n\u003ctd\u003eCredibility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEHRs\u003c\/td\u003e\n\u003ctd\u003e95% hospitals\u003c\/td\u003e\n\u003ctd\u003eIntegration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive Business Model Canvas for Castle Biosciences detailing customer segments (dermatologists, oncologists, patients, payers), channels (direct sales, labs, partners), core value propositions (proprietary genomic diagnostics and prognostic tests), revenue model, partnerships, and cost structure across the 9 BMC blocks. Designed to reflect real-world operations, competitive advantages, risks, and investor-ready insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Castle Biosciences’ business model with editable cells to quickly identify how diagnostic innovation, payer engagement, and commercialization fit together. Saves hours of structuring strategy and is shareable for team collaboration, ideal for boardrooms, teaching, or fast executive summaries.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAssay R\u0026amp;D and optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDesigning, validating, and refining gene expression profiles is core, exemplified by Castle’s 31-gene DecisionDx-Melanoma platform used to stratify risk in melanoma. Analytical and clinical validation studies—performed across multiple independent cohorts—establish performance metrics for assay sensitivity and specificity. Iterative improvements and commercial feedback enhance accuracy and utility while the pipeline expands into adjacent dermatologic and ocular cancers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical evidence generation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProspective and retrospective studies in over 6,000 patients demonstrate prognostic and predictive value for DecisionDx assays, showing significant stratification of recurrence and metastasis risk. Health economic analyses report cost offsets via avoided procedures and downstream savings, supporting payer value propositions. Peer-reviewed publications and \u0026gt;100 conference presentations build clinician trust. Ongoing post-market evidence drives coverage and guideline inclusion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCLIA\/CAP lab operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eEnd-to-end sample processing with strict QC ensures consistent turnaround; as of 2024 Castle Biosciences maintains CAP accreditation and CLIA compliance. Robust SOPs govern accessioning, testing, and reporting across molecular and pathology workflows. Capacity planning and scalable staffing support volume growth and seasonality to meet clinical demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMarket access \u0026amp; reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDeveloping robust payer dossiers, coding strategies, and prior-authorization support ensures Castle Biosciences secures reimbursement for molecular diagnostics and reduces claim denials.\u003c\/p\u003e\n\u003cp\u003eStrategic contracting negotiates favorable rates and coverage policies with payers, while patient assistance programs lower out-of-pocket barriers and improve test uptake.\u003c\/p\u003e\n\u003cp\u003eContinuous policy monitoring and real-time appeals adapt reimbursement tactics to changing coverage rules and maintain revenue resilience.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayer dossiers, coding \u0026amp; prior-authorization\u003c\/li\u003e\n\u003cli\u003eContracting for rates \u0026amp; policy terms\u003c\/li\u003e\n\u003cli\u003ePatient assistance to reduce financial friction\u003c\/li\u003e\n\u003cli\u003eOngoing policy monitoring \u0026amp; appeals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical education \u0026amp; sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMSLs and sales teams educate dermatologists, oncologists, and pathologists on Castle Biosciences assays, using CME content and case studies to demonstrate clinical utility and impact on management; field support drives adoption and adherence to ordering criteria, while clinician feedback informs product updates and training. In 2024 Castle reported continued commercial scale after exceeding 70,000 tested patients.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMSL\/sales clinician outreach\u003c\/li\u003e\n\u003cli\u003eCME + case-study deliverables\u003c\/li\u003e\n\u003cli\u003eField adoption \u0026amp; ordering compliance\u003c\/li\u003e\n\u003cli\u003eFeedback → product\/training updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinically validated gene-expression assay, CAP\/CLIA lab and commercial reach, \u003cstrong\u003e\u0026gt;70,000\u003c\/strong\u003e patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDesign, validate and iterate DecisionDx gene-expression assays (DecisionDx-Melanoma) with ongoing clinical validation and post-market evidence. End-to-end CAP-accredited, CLIA-compliant lab operations ensure QC and scalable throughput supporting commercial demand. Payer engagement, contracting, patient assistance and MSL\/sales outreach drive reimbursement, access and \u0026gt;70,000 tested patients (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTested patients\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;70,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical study patients\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccreditations\u003c\/td\u003e\n\u003ctd\u003eCAP, CLIA\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis preview is the exact Castle Biosciences Business Model Canvas, not a mockup or sample. When you purchase, you’ll receive the same complete, editable file—formatted and structured exactly as shown—ready to download, edit, present, and share. No hidden pages or surprises: the delivered document matches this preview in full.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":55675015790969,"sku":"castlebiosciences-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/castlebiosciences-business-model-canvas.png?v=1755800005","url":"https:\/\/portersfiveforce.com\/products\/castlebiosciences-business-model-canvas","provider":"Porter's Five Forces","version":"1.0","type":"link"}